Drug Profile
Research programme: recombinant human insulin - Adocia
Alternative Names: BioChaperone Lispro U300; Combo insulin fast and slow - Adocia; insulin glulisine/insulin aspart - Adocia; Ultra-concentrated prandial insulin - AdociaLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Adocia
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 27 Jan 2017 Research programme: recombinant human insulin - Adocia is available for licensing as of 27 Jan 2017. http://www.adocia.fr/WP/
- 27 Jan 2017 Eli Lilly terminated the agreement which was signed in December 2014 with Adocia for the joint development and commercialisation of BioChaperone® Lispro
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in France (Parenteral, Injection)